Haastrup, Peter3; Jarbøl, Dorte Ejg3; Hansen, Jane Møller4
1 Research Unit of General Practice, Department of Public Health, Det Sundhedsvidenskabelige Fakultet, SDU2 Medical Gastroenterology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU3 Research Unit of General Practice, Department of Public Health, Det Sundhedsvidenskabelige Fakultet, SDU4 Medical Gastroenterology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU
Background: Antisecretory drugs (ADs) are often prescribed in primary care for upper gastrointestinal symptoms. Reimbursement modifications have been made in Denmark to minimize costs related to use of ADs. However knowledge about development in use of ADs over the past decade and the impacts of the reimbursement modifications is sparse. Research questions: How has use of ADs developed in Denmark 2001-2011? Which impacts have the reimbursement modifications had on the use of ADs? Methods: The Register of Medicinal Product Statistics includes all sales and redeemed prescriptions nationwide covering the entire Danish population of currently 5.5 million inhabitants. The register was searched September 2012 for the ADs proton-pump inhibitors (PPIs) and histamine-2-receptor antagonists. The variables turnover, paid reimbursement, volume sold, sector (primary vs. hospital), age, gender and number of users through the years 2001-2011 were used. Data from prescriptions redeemed by persons younger than 20 years were excluded. Prescriptions for ulcerogenic drugs (acetylsalicylic acid and non-steroidal anti-inflammatory drugs) redeemed by persons aged 65 years and older were included since ulcer prophylaxis could be an indication for prescribing ADs to that age group. Results: PPIs are the far most commonly prescribed AD and 96.5 % are prescribed in primary care. Use of PPIs has increased by 243 % through the past decade. Both number of users and the average individual use has increased. There has not been a change in indications for use of PPIs in the same time range. Use of ulcerogenic drugs among the elderly has stagnated. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use of PPIs. Conclusions: Use of PPIs has increased substantially the past decade. Reimbursement modifications do not seem to have had a substantial influence on the steadily increasing use.